<DOC>
	<DOCNO>NCT02368756</DOCNO>
	<brief_summary>The Endurance 2 Trial determine need ongoing intravitreal aflibercept injection patient diabetic macular edema previously complete VISTA study .</brief_summary>
	<brief_title>Long-Term Efficacy Safety Intravitreal Aflibercept Injections Treatment Diabetic Macular Edema Subjects Who Completed Three Year VISTA-DME Trial ( The Endurance 2 Trial )</brief_title>
	<detailed_description>The Endurance 2 Trial phase IV open label clinical study ass need ongoing intravitreal aflibercept injection 3-year VISTA DME ( VGFT-OD-1009 ) end-point . Subjects treat intravitreal aflibercept injection pro nata ( PRN ) base presence CR-DME ( Clinically Relevant-DME ) . In addition , subject meet re-treatment criterion eligible focal laser treatment every 90 day</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Enrolled Completed VISTA DME ( VGFTOD1009 ) clinical trial Willing able comply clinic visit studyrelated procedure Provide sign informed consent Enrollment trial within 12 week trial activation . Prior treatment antiVEGF therapy study eye within 28 day baseline Pregnant breastfeed woman Sexually active men* woman childbearing potential** unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) . Contraception require men document vasectomy . Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>dme</keyword>
</DOC>